Phibro Animal Health (NASDAQ:PAHC) Upgraded to “Strong-Buy” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday.

PAHC has been the subject of a number of other reports. JPMorgan Chase & Co. began coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price target for the company. Bank of America upped their target price on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. Finally, Barclays upped their target price on Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $16.50.

Phibro Animal Health Stock Down 0.6 %

PAHC opened at $23.59 on Thursday. The business has a 50 day moving average price of $23.27 and a 200 day moving average price of $20.14. Phibro Animal Health has a twelve month low of $9.49 and a twelve month high of $25.98. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. The firm has a market cap of $955.40 million, a P/E ratio of 54.86, a price-to-earnings-growth ratio of 0.62 and a beta of 0.51.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The company had revenue of $273.16 million during the quarter, compared to analyst estimates of $262.44 million. Research analysts forecast that Phibro Animal Health will post 1.61 EPS for the current year.

Insiders Place Their Bets

In related news, Director E Thomas Corcoran acquired 5,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was purchased at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at $500,500. The trade was a 25.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 50.07% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its stake in Phibro Animal Health by 3.1% during the third quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock worth $548,000 after acquiring an additional 729 shares in the last quarter. CWM LLC grew its holdings in shares of Phibro Animal Health by 89.8% during the second quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after purchasing an additional 1,035 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Phibro Animal Health by 7.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock worth $200,000 after purchasing an additional 1,063 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Phibro Animal Health by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after purchasing an additional 1,522 shares during the last quarter. Finally, Cardinal Capital Management grew its holdings in shares of Phibro Animal Health by 4.7% during the second quarter. Cardinal Capital Management now owns 56,027 shares of the company’s stock worth $940,000 after purchasing an additional 2,520 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.